Functional studies of 18 heterologously expressed medium‐chain acyl‐CoA dehydrogenase (MCAD) variants. Issue 6 (26th June 2014)

• Record Type: Journal Article
• Authors: Koster, Kira‐Lee; Sturm, Marga; Herebian, Diran; Smits, Sander H. J.; Spiekerkoetter, Ute
• Is Part Of: Journal of inherited metabolic disease. Volume 37:Issue 6(2014)
• Page Start: 917
• Page End: 928
• Publication Date: 2014-06-26
• Subjects: Metabolism, Inborn errors of -- Periodicals; Metabolism -- Disorders -- Periodicals; 616.39042
• DOI: 10.1007/s10545-014-9732-5
• Languages: English
• ISSNs: 0141-8955

Abstract

Abstract: Medium‐chain acyl‐coenzyme‐A dehydrogenase (MCAD) catalyzes the first step of mitochondrial beta‐oxidation for medium‐chain acyl‐CoAs. Mutations in the ACADM gene cause MCAD deficiency presenting with life‐threatening symptoms during catabolism. Since fatty‐acid‐oxidation disorders are part of newborn screening (NBS), many novel mutations with unknown clinical relevance have been identified in asymptomatic newborns. Eighteen of these mutations were separately cloned into the human ACADM gene, heterologously overexpressed in Escherichia coli and functionally characterized by using different substrates, molecular chaperones, and measured at different temperatures. In addition, they were mapped to the three‐dimensional MCAD structure, and cross‐link experiments were performed. This study identified variants that only moderately affect the MCAD protein in vitro, such as Y42H, E18K, and R6H, in contrast to the remaining 15 mutants. These three mutants display residual octanoyl‐CoA oxidation activities in the range of 22 % to 47 %, are as temperature sensitive as the wild type, and reach 100 % activity with molecular chaperone co‐overexpression. Projection into the three‐dimensional protein structure gave some indication as to possible reasons for decreased enzyme activities. Additionally, six of the eight novel mutations, functionally characterized for the first time, showed severely reduced residual activities < 5 % despite high expression levels. These studies are of relevance because they classify novel mutants in vitro on the basis of their corresponding functional effects. This basic knowledge should be taken into consideration for individual management after NBS.